Top Markets
Coin of the day
Anthera Pharmaceuticals, Inc. Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals, Inc.

ANTH
Rang in Aktien #42276
Anthera Pharmaceuticals, Inc., a biopharmaceutical enterprise, concentrates on... Anthera Pharmaceuticals, Inc., a biopharmaceutical enterprise, concentrates on developing and commercializing therapeutic solutions for conditions with significant unmet medical needs. The company's pipeline includes Sollpura, an investigational non-porcine pancreatic enzyme replacement therapy in Phase III clinical trials for individuals with exocrine pancreatic insufficiency. It is also advancing Blisibimod, currently in Phase II clinical evaluation for B-cell mediated autoimmune diseases, such as immunoglobulin A nephropathy (IgA nephropathy). Anthera holds licensing agreements with Amgen, Inc. and Eli Lilly and Company. Founded in 2004, the company's base of operations is in Houston, Texas.
Aktienkurs
$0.0001
Zuletzt synchronisiert: 2026-08-11
Marktkapitalisierung
$2.62K
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Anthera Pharmaceuticals, Inc. (ANTH)

Kategorie

Dividendenrendite-Verlauf für Anthera Pharmaceuticals, Inc. (ANTH)
Dividendenrendite (TTM) von Anthera Pharmaceuticals, Inc. (Aktienkürzel: ANTH) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Anthera Pharmaceuticals, Inc. (ANTH) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber